Cyclopentanohydrophenanthrene Ring System Patents (Class 514/26)
-
Patent number: 8541382Abstract: A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin.Type: GrantFiled: February 1, 2011Date of Patent: September 24, 2013Assignee: Sirbal Ltd.Inventor: Nadav Shraibom
-
Publication number: 20130244960Abstract: Using a Pharmaceutically Suitable Preparation containing one more Cardio Glycosides such as THEVETIN B, THEVETIN A, PERUVOSIDE, THEVOFOLIN, OLEANDRIN, NERIIFOLIN, THEVETOXIN Derived and or Extracted from the Yellow Oleandrin Plant (Oleandrin Peruviana), White Oleandrin Plant (Nerium Oleander) and or other Plants in the Apocynaceae Genus, in the Dogbane Plant Family and or extracted from plants and or animals including plants and animals such as Foxglove or synthetic man-made, and or a combination of synthetic and natural thereof in Pharmaceutically Suitable Preparation in a Pharmaceutically Suitable Dose, example orally or intravenously, of which the Prescriber of the said Preparation, or Doctor, based on the overall health of the Patient will prescribe the best Dosage, The Best Mode of Dosage example orally or intravenously, which is best suited to have the Most Desirable Therapeutic Effect on the PatientType: ApplicationFiled: March 15, 2012Publication date: September 19, 2013Inventor: Kingsley Yianomah Quartey
-
Publication number: 20130225515Abstract: Methods of isolating biologically active molecules from an organism, for example from a fungus, are described. The methods involve isolating an active molecule which possesses a specific biological activity on, in or against wild-type yeast cells, but not on, in or against yeast cells that express a given ABC transporter from a given organism, including but not limited to Magnaporthe species such as Magnaporthe grisea. In preferred embodiments, the biological activity is antifungal activity. In most preferred embodiments, the antifungal activity is against a human pathogen, including but not limited to Candida albicans. The biologically active molecules can be formulated as pharmaceutical compositions and used to treat fungal infections in a subject, including a human subject.Type: ApplicationFiled: February 8, 2013Publication date: August 29, 2013Applicant: TEMASEK LIFE SCIENCES LABORATORY LIMITEDInventor: Temasek Life Sciences Laboratory Limited
-
Patent number: 8513203Abstract: The present disclosure relates to a composition comprising Trigoneoside Ib and Vicenin-1 for treatment and management of Goodpasture's disease, Glomerulonephritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Idiopathic Thrombocytopenia Purpura. The present disclosure also relates to a method of obtaining the said composition from Trigonella foenum-graecum.Type: GrantFiled: June 14, 2011Date of Patent: August 20, 2013Assignee: Indus Biotech Private LimitedInventors: Sunil Bhaskaran, Mohan Vishwaraman
-
Publication number: 20130209579Abstract: This invention relates to therapeutic combinations comprising a platinum-based anti-neoplastic agent, such as cisplatin, and an extract from a species of the genus Nerium, such as Nerium oleander, as well as methods of using such combinations to treat subjects, including humans, suffering from certain cancers, such as prostate cancer, melanoma, pancreatic cancer, lung cancer, breast cancer, or colorectal cancer.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: Nerium Biotechnology, Inc.Inventors: Dennis R. Knocke, Joseph B. Nester, Ioannis Papasotiriou
-
Publication number: 20130210752Abstract: Methods of screening, identifying and isolating HMG-CoAR inhibitors are disclosed herein. In particular, said method is useful for screening natural raw products. The present invention also provides potent HMG-CoAR inhibitors for treatment and prevention of diseases and conditions associated with elevated cholesterol and/or blood lipid levels.Type: ApplicationFiled: February 8, 2013Publication date: August 15, 2013Applicant: HONG KONG BAPTIST UNIVERSITYInventor: Hong Kong Baptist University
-
Publication number: 20130209379Abstract: Cosmetic formulations suitable for application to the lips are described herein. The lip cosmetic formulations can contain at least caffeine, extract of Hoodia gordinii and extract of green tea. The lip cosmetic formulations can also contain a bioavailable chromium source and/or L-carnitine. Optionally, the lip cosmetic formulations can also contain a sunscreen.Type: ApplicationFiled: June 16, 2011Publication date: August 15, 2013Applicant: Pacific Shore Holdings, IncInventors: Matthew Mills, Allan Kurtz
-
Publication number: 20130209505Abstract: The invention provides a crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester or its tautomer. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases.Type: ApplicationFiled: February 14, 2013Publication date: August 15, 2013Inventor: Miroslav RAPTA
-
Publication number: 20130203690Abstract: Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicant: Boehringer Ingelheim Vetmedica GmbHInventors: Juergen Daemmgen, Olaf Joens, Rainer Kleeman, Christian Troetschel, Andrea Vollmar
-
Patent number: 8497249Abstract: CAY-1 is a fungicidal saponin from the cayenne pepper (Capsicum frutescens) fruit. The saponins 1081 and 919, closely elute with, and are close structural relatives of, CAY-1. Saponin 1081 is poorly antifungal while 919 has no antifungal properties. Nongerminated and germinating conidia of Aspergilus flavus, A. fumigatus, A. niger, Fusarium oxysporum, F. solani, and F. verticilioides were tested against pure CAY-1 and CAY-1:1081:919 at ratios of 8:1:1, 6:2:2 and 4:3:3 and efficacy was determined after various incubation times. Pure CAY-1 and all saponin mixtures were significantly (p<0.001) lethal to the germinating conidia of A. flavus, A. niger, and F. solani. All saponin mixtures were equal or superior to pure CAY-1 in antifungal properties. Mixtures of the naturally occurring inactive or poorly fungicidal saponins with reduced levels of CAY-1 display superior fungicidal properties when compared to pure CAY-1 at the same dose levels.Type: GrantFiled: October 2, 2009Date of Patent: July 30, 2013Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Anthony J. De Lucca, Stephen M. Boue
-
Publication number: 20130184218Abstract: A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.Type: ApplicationFiled: July 19, 2012Publication date: July 18, 2013Inventors: Dennis J. Paul, Harry J. Gould
-
Patent number: 8486900Abstract: The invention concerns an extract of Centella asiatica comprising more than 75 wt. % of a mixture of madecassoside, terminoloside and asiaticoside, relative to the extract total weight, an extract of Centella asiatica comprising more than 95 wt. % of a mixture of madecassoside and terminoloside relative to the extract total weight and their use for regulating inflammatory mechanisms.Type: GrantFiled: March 21, 2012Date of Patent: July 16, 2013Assignee: Bayer Consumer Care AGInventors: Alain Loiseau, Gérard Sene, Eric Theron
-
Patent number: 8487090Abstract: A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5˜10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1˜30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40˜100° C., the ratio of these two is 1:1˜300, add water after the solvent is recycled under reduced pressure; another kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution contains 0.1˜2 mg/ml of 20(R) of the ginsenoside Rg3, the preparation: add 0.1˜5% of ginsenoside solution to 20˜65% of adjuvant B{circle around (3)}{circle around (4)} at the temperature of 60˜100° C., main material to adjuvant B=1:100˜400, add water after the solvent is recycled under reduced pressure.Type: GrantFiled: May 18, 2007Date of Patent: July 16, 2013Assignee: Dalian Fusheng Natural Medicine Development Co., Ltd.Inventors: Li Fu, Qi Lu
-
Patent number: 8486899Abstract: To provide an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and is used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains 3-O-?-D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.Type: GrantFiled: November 18, 2009Date of Patent: July 16, 2013Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Miyuki Tanaka, Kouji Nomaguchi, Tatsuya Ehara
-
Publication number: 20130178430Abstract: This invention is for the compound containing ginsenoside Rg3 as an active ingredient to prevent and treat Hepatitis C virus infection. Specifically, the ginsenoside Rg3 of this invention demonstrated the predominant antiviral activities and apotosis actions in a dose-dependent manner in the Hepatitis C virus infected cells (Huh 7.5.1). Confirmed that it reduces the levels of TNF-? and thioredoxin significantly, and increases phospho-NF?B. It also demonstrated same effectiveness as PegInterferone alpha-2b(PegIFN a-2b, Hepatitis C therapeutics), and has no cytotoxicity to human bodies. Thus, it may be used safely as an active ingredient of medical/pharmaceutical and health food compounds for preventing or treating Hepatitis C.Type: ApplicationFiled: November 30, 2012Publication date: July 11, 2013Inventor: Jae-Young JANG
-
Publication number: 20130177627Abstract: The present invention relates to pharmaceutical composition containing a physiologically effective dose of a nanoparticle triterpene glycoside or nanoparticle triterpene complex, wherein said complex is a liposome encapsulated compound, or exosome-encapsulated compound.Type: ApplicationFiled: November 19, 2012Publication date: July 11, 2013Inventors: Linda Einbond, Stepehn Redenti
-
Publication number: 20130178431Abstract: The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.Type: ApplicationFiled: December 27, 2012Publication date: July 11, 2013Applicants: CENTROSE, LLCInventor: Jill Hutchinson-Bollettieri
-
Publication number: 20130164265Abstract: This invention provides compositions and methods of manufacturing such compositions that employ GRAS compounds which can act to promote the generation of stem, epidermal or other skin cells in the epidermis, activation of collagen synthesis, activation of hyaluronic acid synthesis, enhanced skin hydration, and dermal healing by stimulating stem cell and fibroblast migration to sites of needed repair. These compositions and methods are useful for rejuvenating the skin and for treating some skin-related aging or other dermal damaging conditions, including wrinkle reduction and treatment of minor dermal wounds.Type: ApplicationFiled: December 21, 2011Publication date: June 27, 2013Inventors: Dana FLAVIN, Sigrid OBENLAND
-
Patent number: 8466140Abstract: Described are mitochondria-targeted anti-tumor agents, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation.Type: GrantFiled: September 10, 2008Date of Patent: June 18, 2013Assignee: University of MassachusettsInventors: Dario C. Altieri, Byoung Heon Kang
-
Patent number: 8455252Abstract: Disclosed herein are materials and methods for sensitizing multidrug resistant cancer cells that express ABCG2 and related proteins members of a family of ATP-binding transporter superfamily that mediate drug efflux found in some types of multidrug resistant cancer cells. A series of compounds, including (N-(4-chlorophenyl)-2-[(6-{[4,6-di(4-morpholinyl)-1,3,5-tri-azin-2-yl]amino}-1,3-benzothiazol-2-yl)sulfanyl]acetamide), specifically inhibits ABCG2 and can be used to boost the bio-avail-ability of one or more effective cancer killing drugs, making it possible to use certain widely used chemotherapeutic reagent to treat multidrug resistance cancers. Using these compounds in combination with chemotherapeutic drugs that are substrates for ABCG2 and related proteins may also find utility in treating cancer cells that are not currently identified as multi-drug resistant. Additionally, these compounds appear to accelerate the intercellular degradation of ABCG2 and related proteins.Type: GrantFiled: October 24, 2009Date of Patent: June 4, 2013Assignee: Indiana University Research and Technology Corp.Inventors: Jian-Ting Zhang, Jing Qi, Hui Peng, Zizheng Dong
-
Publication number: 20130136772Abstract: The present invention relates to a method of inhibiting pro-inflammatory and T-cell mediated cytokines, said method comprising step of administering to a subject in need thereof a therapeutically effective amount of colocynthin and/or its derivatives. The invention also relates to a method of inhibiting T-cell surface markers and to a method of regulating immune response by colocynthin and/or its derivatives.Type: ApplicationFiled: August 30, 2011Publication date: May 30, 2013Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Anjali Pardey, Shivakumar Ranganath
-
Patent number: 8440632Abstract: Provided herein are ginsenoside compositions comprising at least 10% (w/w) of a protopanaxadiol type of ginsenoside suitable for administration to a subject. Also provided are methods using the ginsenoside compositions for reducing acetaldehyde concentrations, preventing or ameliorating a symptom of elevated acetaldehyde concentration, or reducing the risk of diseases or disorders caused by the intake of ethyl alcohol.Type: GrantFiled: January 23, 2009Date of Patent: May 14, 2013Assignee: Raptor Therapeutics Inc.Inventors: Thomas E. Daley, Michael Tempesta
-
Publication number: 20130109639Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: November 1, 2012Publication date: May 2, 2013Inventors: Adam D. HUGHES, Erik FENSTER, Melissa FLEURY, Roland GENDRON
-
Publication number: 20130109638Abstract: The invention relates to the field of the dermatologic therapy for acne; particularly it relates to a composition for treating acne, particularly nodular acne. The composition is made based on plant source proanthocyanidins and terpenoides.Type: ApplicationFiled: November 1, 2011Publication date: May 2, 2013Applicant: FOLIA HEALTH PRODUCTS, S.A. DE C.V.Inventor: Daniel Robert MILLER-GIBBONS
-
Publication number: 20130101679Abstract: The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.Type: ApplicationFiled: December 5, 2012Publication date: April 25, 2013Inventors: Shin YAZAWA, Toyo Nishimura, Takayuki Asao
-
Publication number: 20130102549Abstract: Provided are a VEGF production promoter, a hair quality improver, and an external preparation for skin, each of which has a VEGF production promoting activity and can be used as a pharmaceutical agent, a cosmetic, a food, or a material therefor. The VEGF production promoter, the hair quality improver, and the external preparation for skin each comprises, as an active ingredient, a cycloartane-type glycoside represented by the following general formula (1) (where R represents a xylose residue or an arabinose residue, and the ring D moiety represents any one of the following moieties a to f (where R1 represents a hydrogen atom or a methyl group, R2 represents a hydrogen atom or an acetyl group, R3 represents a hydrogen atom or a hydroxyl, group, R4 represents a hydrogen atom or a hydroxyl group, and Ac represents an acetyl group)).Type: ApplicationFiled: July 1, 2011Publication date: April 25, 2013Inventors: Akiyo Kameyama, Sachie Ueda
-
Patent number: 8426471Abstract: Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, and R4 are as defined herein.Type: GrantFiled: July 13, 2012Date of Patent: April 23, 2013Assignee: Topokine Therapeutics, Inc.Inventors: Murat V. Kalayoglu, Michael S. Singer
-
Publication number: 20130079293Abstract: Isolated compounds from adelostemma gracillimum refined fractions and compositions containing the compounds are provided by the present invention. Adelostemma gracillimum refined fractions and the extraction process thereof are also provided by the present invention. The uses of the compounds and the adelostemma gracillimum refined fractions for inhibiting the activities of NMDA receptor or amyloid-beta peptide, for improving memory, and for treating neurodegenerative diseases, neuropathological conditions or epilepsy are further provided by the present invention.Type: ApplicationFiled: March 18, 2011Publication date: March 28, 2013Applicant: BIOTECHNOLOGY RESEARCH CORPORATION LIMITEDInventors: Nancy Yuk-yu Ip, Fanny Chui-Fun Ip, Shengjun Guo
-
Publication number: 20130071322Abstract: A method for medical treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres may be administered for void filling, tissue bulking, non-vasculature occlusion, body fluid absorption, and delivery of medications.Type: ApplicationFiled: September 26, 2012Publication date: March 21, 2013Applicant: E I DU PONT DE NEMOURS AND COMPANYInventor: Garret D. Figuly
-
Publication number: 20130072451Abstract: A low viscosity personal care composition comprising from about 10 % to about 99% of water, from about 0.01% to about 20% of a suspended particulate material, from about 0.01% to about 5% of an acrylic polymer, wherein the composition has a viscosity of from about 80 to about 1000 mPa·s, and a pH of from about 4 to about 9, wherein the acrylic polymer provide a selection yield value of at least 0.11 Pa. An array of two or more low viscosity personal care compositions, wherein one of the personal care compositions comprises said particulate material at a level different from those in the other personal care compositions.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Inventors: Qiaolu LU, Paul (Robert) Tanner, Robert (Bao Kim) Ha
-
Publication number: 20130065842Abstract: Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as ROR?t modulators that have a formula represented by the following: and wherein n1, n2, R1, R2, R3, and R4 are as described herein. These compounds may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: ApplicationFiled: March 11, 2011Publication date: March 14, 2013Inventors: Dan Littman, Jun R. Huh, Wenwei Huang, Ruili Huang
-
Publication number: 20130059804Abstract: As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: ApplicationFiled: August 3, 2012Publication date: March 7, 2013Applicant: SATORI PHARMACEUTICALS, INC.Inventor: Mark A. Findeis
-
Publication number: 20130059021Abstract: A perfluoro(n-butylcyclohexane) composition is disclosed with numerous uses including topical and cosmetic applications, e.g., for application to the periocular skin or for the topical treatment of pruritus.Type: ApplicationFiled: September 6, 2012Publication date: March 7, 2013Inventors: Aharon Grossman, Chris Stern, Richard Kiral, Gary Clauson, Gerald Klein
-
Patent number: 8389697Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.Type: GrantFiled: January 27, 2012Date of Patent: March 5, 2013Assignee: Genentech, Inc.Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina
-
Publication number: 20130052160Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition.Type: ApplicationFiled: April 1, 2011Publication date: February 28, 2013Applicant: INSTITUT GUSTAVE ROUSSYInventors: Laurence Zitvogel, Guido Kroemer, Nicolas Delahaye, Yuting Ma, Oliver Kepp
-
Patent number: 8377894Abstract: Compounds having a cyclolanostane skeleton such as 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan-3-ol are used as an active ingredient of a drug and food or drink for improving pancreatic functions.Type: GrantFiled: February 28, 2006Date of Patent: February 19, 2013Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Miyuki Tanaka, Eriko Misawa, Noriko Habara, Muneo Yamada
-
Publication number: 20130040903Abstract: Pharmaceutical compositions or functional foods for treating depression and anxiety comprising ginseng saponin (Rgl+Rbl), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression and anxiety paroxetine and diazepam in the art, the present invention has significant anti-depression and anxielytic efficacy.Type: ApplicationFiled: October 18, 2012Publication date: February 14, 2013Inventors: Yu-Fen Chi, Zuoguang Zhang
-
Publication number: 20130040001Abstract: The present invention provides a method of processing animal skin, comprising the steps of: 1) providing dry animal skin containing 7-38 wt % water; 2) rehydrating and softening the said dry animal skin, and obtaining softened wet skin; 3) mixing the said softened wet skin with water, and grinding the mixture to a slurry; 4) obtaining a solid product through a crosslink of collagen proteins in the said slurry; wherein, rehydrating the said dry animal skin is performed through soaking the dry animal skin in 0-55° C. water till the animal skin contains 40-50 wt % water; and softening the said dry animal skin comprises a step of heating the rehydrated dry animal skin.Type: ApplicationFiled: October 19, 2012Publication date: February 14, 2013Inventor: Jingmin Zheng
-
Patent number: 8361973Abstract: The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.Type: GrantFiled: August 7, 2009Date of Patent: January 29, 2013Assignee: Centrose, LLCInventors: Mohammed S. Shekhani, James R. Prudent, Jill Hutchinson Bollettieri
-
Publication number: 20130023488Abstract: Compounds and compositions for reducing intracellular lipid accumulation in a cell are described herein. These compounds are useful for the treatment and prevention of lipid/glycogen disorders, as well as for the treatment and prevention of obesity. A high throughput screen for identifying compounds that reduce intracellular lipid accumulation in cells is also provided.Type: ApplicationFiled: July 19, 2012Publication date: January 24, 2013Applicant: The General Hospital CorporationInventor: Sean Wu
-
Publication number: 20130023487Abstract: Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.Type: ApplicationFiled: July 22, 2011Publication date: January 24, 2013Inventors: Paul Kiprono Chepkwony, Maria Medina, Mitchell Medina
-
Patent number: 8357786Abstract: Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid/glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, and accelerates the reduction of body fat and blood glucose, thereby improving obesity, diabetes, and hyperlipidaemia. The disclosed AMPK activating material contains, as active ingredients having an improving and treating effect on metabolic syndrome, including obesity, diabetes, and hyperlipidaemia, a novel compound 2?,3?,12?-trihydroxydammar-20(22)-E,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin A, and a novel compound 2?,3?,12?-trihydroxydammara-20,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin B.Type: GrantFiled: January 29, 2010Date of Patent: January 22, 2013Assignee: TG Biotech Co., Ltd.Inventors: Tae Lin Huh, He Bok Song, Ji Eun Kim, So Young Joon, Won Keun Oh
-
Publication number: 20130012462Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, methods of enhancing the brain's cognitive functions and methods of treating depression, anxiety and cachexia induced by a chronic disease in mammals and humans.Type: ApplicationFiled: January 5, 2012Publication date: January 10, 2013Applicant: Biotechnology Research Corporation LimitedInventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
-
Publication number: 20130013334Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.Type: ApplicationFiled: August 31, 2012Publication date: January 10, 2013Applicant: Millennium Pharmaceuticals, Inc.Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
-
Publication number: 20120329738Abstract: Enhanced methods have been discovered, using either sonication or homogenization followed by increased temperature and pressure, to solubilize compounds using diterpene glycosides and to produce a powder form of the compound-solubilizer complex than can be reconstituted in water. Without the diterpene glycoside, the compounds were insoluble or sparingly soluble in water, including some fat-insoluble vitamins. Water solutions of these compounds were made using a diterpene glycoside solubilizer, for example, rubusoside. The compound-solubilizer complex was then dehydrated to a stable powder that could then be reconstituted with water. A reconstituted drug-solubilizer complex (curcumin-rubusoside) was shown to be effective on reconstitution. In addition, the diterpene glycoside, rubusoside, was shown to be an inhibitor of permeability glycoprotein (P-gp), and will thus increase gastrointestinal absorption of certain drugs administered with rubusoside.Type: ApplicationFiled: October 15, 2010Publication date: December 27, 2012Inventor: Zhijun Liu
-
Publication number: 20120322752Abstract: The present invention provides solid dispersion, comprising: 20-O-?-D-glucopyranosyl-20(S)-protopanaxadiol which is a pharmacologically active ingredient; and a saturated polyglycolized glyceride which is a lipid matrix. The solid dispersion of the present invention has effects of increasing dissolution rate of 20-O-?-D-glucopyranosyl-20(S)-protopanaxadiol.Type: ApplicationFiled: December 8, 2009Publication date: December 20, 2012Inventors: Sung Kyun Lee, Yong-Duck Park, Jae Won Jang, Bong Hang Hur, Sang Cheol Chi
-
Publication number: 20120321688Abstract: Method of using saponins from at least one plant of the Gleditsia genus, or an extract of at least one plant of the Gleditsia genus including saponins, for controlling, by ingestion, land or aquatic mollusc pests. The molluscicidal active principle, compositions containing the same, and methods for controlling mollusc pests are also described.Type: ApplicationFiled: February 9, 2011Publication date: December 20, 2012Applicant: DE SANGOSSEInventors: Xavier Crebassa, Herve Caruel, Frederic Mercier, Ricardo Manuel Guillermo San Martin Gamboa
-
Publication number: 20120322753Abstract: The production method prepares a solid preparation by dissolving water-insoluble and/or water indissolvable alkaline active pharmaceutical ingredient in an acidifier-containing acid solution to obtain medicated acid liquid; homogeneously mixing alkalizer, adjuvants and the medicated acid liquid, and carrying out wet granulation. The alkalizer is a reagent to reduce the acidity of the mixture of the alkalizer and the medicated acid liquid relative to the acidity of the medicated acid liquid. The preparation method avoids the problems in mechanical pulverization, such as environmental pollution, great loss and serious security risks. This method is simply operated, has high safety coefficient and is convenient for industrialized production. Also disclosed is the solid preparation produced by the method. The solid preparation produced by the method has better dissolution performance than that produced by prior art, and has better or at least equivalent stability and content uniformity with prior art.Type: ApplicationFiled: December 28, 2010Publication date: December 20, 2012Applicants: SHANGHAI ZHONGXI SUNVE PHARMACEUTICAL CO., LTD., SHANGHAI ZHONGXI PHARMACEUTICAL COMPANYInventors: Siji Zheng, Bo Tan
-
Publication number: 20120321704Abstract: A compound sea cucumber product, preparation method thereof and dosage forms thereof are disclosed. A fresh sea cucumber is cut open, the viscus thereof is taken out, and they are well-cleaned respectively and put into an airtight container; at 70˜130° C., gelatinate for 1 min˜20 hours; thereafter freeze-dry till the water content is less than 10 wt %; apply coarse crushing till the fineness reaches 10˜300 mesh; then apply ultra-micro crushing by means of an airflow crusher until the fineness reaches 100˜3000 mesh; lastly apply nanometer crushing by means of high-energy ball grinding mill till the fineness reaches 10˜1000 nm. The nanometer sea cucumber extract is mixed with panax pseudo-ginseng saponins extract at the proportion of 99˜80 wt %:1˜20 wt %.Type: ApplicationFiled: March 3, 2011Publication date: December 20, 2012Applicant: DALIAN HAIYANTANG BIOLOGY CO.,LTD.Inventors: Jian Jiao, Junjie Shao
-
Publication number: 20120316122Abstract: The present invention relates to a pharmaceutical composition for combating a thrombotic disease and a method for making the same and a use thereof. The pharmaceutical composition mainly comprises timosaponin AIII and timosaponin BII, and optionally pharmaceutically acceptable excipients, characterized in that the amount of timosaponin AIII is greater than or equal to the amount of timosaponin BII. The present invention further relates to a use of timosaponin AIII and timosaponin BII in manufacturing a medicament or product for the prophylaxis or to treatment of a thrombotic disease. The present pharmaceutical composition can not only bring about effects of prophylaxis or treatment of a thrombotic disease, but also alleviate blood bleeding or bleeding tendency in patients.Type: ApplicationFiled: September 7, 2009Publication date: December 13, 2012Applicant: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES ,PLAInventors: Baiping Ma, Yuwen Cong, Liping Kang, Yue Gao, Dawei Tan, Chengqi Xiong, Yang Zhao